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T
 
he goal of this panel was to identify key con-
tentious methodology issues in conducting
healthcare pharmacoeconomic evaluations in the
context of retrospective studies and claims data.
Its specific objectives were to:
• identify and prioritize the key issues associated
with pharmacoeconomic and outcomes re-
search studies using retrospective and claims
data;
• identify a plan of action to resolve these issues;
• recommend next steps.
 
Background and Context
 
Pharmacoeconomic analyses can be conducted
within the context of clinical studies or by using
retrospective databases. Randomized clinical trials
(RCTs) and observational studies, specifically ret-
rospective database analyses, answer different
questions. For example, most RCTs are designed
to measure efficacy, not effectiveness. Existing da-
tabases can provide effectiveness and “real-world”
data. Cost-effectiveness analyses utilizing retro-
spective databases can provide real-time, relevant,
and comprehensive decision support.
Retrospective analyses are relatively inexpen-
sive to perform and can be done quickly. They are
reflective of specific populations that cannot be
easily studied using RCTs, and for which data
may be difficult to obtain. Relative to RCTs, ret-
rospective studies tend to cover more realistic time
frames and are not constrained by the limitations
of a set trial period. The perspective of a particular
organization’s experience can be obtained, and
large samples can be surveyed. Usually, the sample
sizes of retrospective databases are much larger
than RCTs, enhancing their statistical power to
detect important differences in outcomes. Retro-
spective databases encompass a wealth of vari-
ables, and analyses of these data can be used for
benchmarking purposes and for capturing real-
world prescribing patterns. Notwithstanding the
advantages of retrospective database analyses,
there are challenges that face these analyses when
used for health economic evaluations.
 
Problem Statement
 
Healthcare decision-makers require rapid access
to information. The evidence that assists decision-
makers to draw conclusions often has not been
available. Both RCTs and retrospective methods
using existing databases provide such informa-
tion, and they typically answer different questions.
Most RCTs are designed to measure efficacy, not
effectiveness. “Real-world” data can be provided
by database studies. The validity of retrospective
analyses is often questioned because of the poten-
tial for selection bias, confounding factors, spon-
sorship, data quality, and privacy issues. In addi-
tion, since there may be a time lag in the
availability of information about new therapies
and its incorporation into and availability from
databases, the timeliness of the economic evalua-
tions resulting from a retrospective analysis can be
questioned.
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Issues
 
Eight key issues were identified, which are ad-
dressed in this document:
1. What research questions can be answered by
retrospective analyses?
2. What data sources are available to answer
these questions?
3. How is cost-effectiveness measured using auto-
mated databases?
4. How can data quality within a database be
evaluated?
5. What types of statistical methods can be uti-
lized to control for treatment effects?
6. What potential types of bias exist in retrospec-
tive database analyses?
7. What alternative methods for assessing selec-
tion bias are available?
8. How can transparency be ensured in retrospec-
tive database analyses?
 
What Research Questions Can Be Answered by 
Retrospective Database Analyses?
 
The types of economic studies that can be con-
ducted using automated databases include cost-
consequence, cost-effectiveness, and cost-of-illness
analyses. Currently, cost-utility analyses are rarely
addressed because of the lack of utility data cap-
tured in databases.
Of paramount importance to utilizing retro-
spective database analysis for health economic
evaluations is the careful crafting of the research
question. This question must be derived at the
outset from the perspective of the appropriate par-
ties, and such perspective may include society, the
provider, the payer, or the patient.
Crafting the question is critical to the success of
a project since it drives all other aspects of the re-
search project. It dictates:
• how the literature review is performed;
• the study objectives;
• the definitions of health outcomes and vari-
ables to be studied;
• the study design, including sample size;
• the time frame to be evaluated;
• data source(s), validation, and analyses;
• the budget.
 
What Data Sources Are Available to Answer
the Question?
 
The types of data sources that can be utilized for
health economic evaluations based on retrospec-
tive analysis include:
• electronic medical records (integrated modules
of pharmacy, laboratory, and clinical data-
bases);
• claims data such as that from managed care
databases, the Healthcare Finance Administra-
tion (HCFA), the Department of Defense, Vet-
erans Affairs, self-insured employers, and phar-
macy benefit managers (PBMs);
• encounter data such as that from a staff/group
model of health maintenance organizations
(HMOs);
• expert opinion;
• results of published literature, such as meta-
analyses;
• patient registries;
• national survey databases, such as the Medical
Expenditure Panel Survey (MEPS), formerly
the National Medical Expenditure Survey
(NMES).
 
How Is Cost-Effectiveness Measured Using 
Automated Databases?
 
Cost-effectiveness studies require comparison of
two or more competing therapeutic options. It is
possible to measure cost-effectiveness using auto-
mated databases. First, one must determine if the
particular database is appropriate to answer the
question. Evaluation depends on the disease in
question and availability of the outcome measures
of effectiveness. For example, it would be inappro-
priate to select a hospital discharge database to
evaluate lithotripsy use in kidney stones if the pro-
cedure is performed on an outpatient basis. Data-
bases containing both outcome and cost infor-
mation are required to perform cost-effectiveness
analyses, including, for example, administrative
claims as well as laboratory and prescription data.
In some cases, linkage of databases might be ap-
propriate to address some research questions. An
example of database linkage for estimating cost of
care for patients with cancer has been published [1].
Outcome measures can include, for example, dia-
betic ketoacidosis episodes or amputations avoided,
which are coded using the International Classifica-
tion of Disease (ICD-9) or Current Procedural
Terminology (CPT-4) codes. Intermediate outcome
measures can also be used, such as the percentage
reduction of low density lipoprotein cholesterol
rather than occurrence of a major cardiovascular
event. Currently, databases do not usually contain
quality-of-life (QoL) or utility data. However, QoL
data are beginning to be collected, such as in the
Patient Outcomes Research Teams (PORT) data-
bases, in selected managed care databases, and in
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the managed care Health Plan Employer Data and
Information Set (HEDIS) that captures data from
questionnaires like the SF-36.
 
How Can Data Quality within a Database
Be Evaluated?
 
Assessing the accuracy and completeness of the
database [2,3] is integral to a research study based
on automated database information. Data checks
must be performed regularly and consistently.
Points to be considered include:
• Are there missing data elements, and if so,
what percentage is missing?
• Is the cohort continuously tracked over the pe-
riod of interest?
• Is it possible to trace services and diagnoses
across healthcare settings (e.g., hospitals, nurs-
ing homes, and clinics)?
• Were all relevant diagnoses and procedure
codes accurately recorded for the visit or epi-
sode of care?
• Are data recorded uniformly using widely ac-
cepted recording standards?
• Was the accuracy of the diagnostic and utiliza-
tion records verified with chart reviews or
benchmarking?
• Were logical consistency checks performed,
such as searching the database for illogical
matches (e.g., those between “hysterectomies”
and “males”)?
• Are there unique identifiers for each family
member?
• Were events recorded when they actually oc-
curred?
• Is population-denominator data available? That
is, does the database contain enrollment infor-
mation that enables the identification of indi-
viduals without healthcare utilization?
 
What Types of Statistical Methods Can Be Utilized to 
Control for Treatment Effects?
 
With retrospective database studies in particular,
it is important to control for as many confounding
variables as possible. A need exists for statistical
methods to control for these effects, which implies
that multivariate analysis should be performed
whenever possible.
 
What Potential Types of Bias Exist in Retrospective 
Database Analyses?
 
The potential areas for bias [4] within retrospec-
tive database analyses form a long list, including,
but not limited to the following examples.
 
Selection Bias.
 
Individuals are not typically ran-
domly assigned to health plans or treatments. Esti-
mates of the effects and costs can be biased due to
a correlation between unobserved factors associ-
ated with treatment selection and outcomes, such
as baseline health status. Sample selection bias is
often referred to by other names. For example,
vintage bias, which is due to variation in physician
training and practice styles or in availability of
technologies resulting in confounding measures of
costs and outcomes, is a specific type of selection
bias.
 
Bias from Censoring of Data.
 
Bias can be intro-
duced when the length of time that individuals are
observed is correlated with their outcomes. For
example, some studies may impose a minimum el-
igibility period that leads to the omission of sub-
jects with short-term eligibility. If the reasons for
the failure to meet the minimum eligibility criteria
are correlated with utilization patterns, such as a
death, then a biased conclusion will result. Simi-
larly, if the length of the observation period varies
for individuals, then bias may be introduced be-
cause of failure to observe utilization that oc-
curred after the observation period ended (e.g.,
there is less opportunity to observe service utiliza-
tion patterns for patients treated with relatively
new drugs).
 
Measurement Error Bias.
 
There are numerous
sources of error in measurement of data that can
introduce bias. For example, specialists may tend
to code diagnoses with more specificity than gen-
eral practitioners. Similarly, fee-for-service provid-
ers may have an incentive to document diagnoses
and services relative to at-risk providers who may
have an incentive to minimize the burden of docu-
mentation. Recall bias is yet another form of mea-
surement error. Recall bias refers to the tendency,
on the part of respondents, to recall service utiliza-
tion that occurred more recently with greater ac-
curacy than service utilization that occurred in the
more distant past.
 
Misspecification Bias.
 
As with measurement er-
ror, there are a variety of forms of misspecifica-
tion errors that can lead to biased estimates. These
include omitted variables, incorrect function form,
and using single equation models when a multi-
equation model is more appropriate.
 
Investigator Bias/Obsolescence Bias.
 
There are
sources of bias that may be introduced that are
not directly a function of retrospective data them-
selves. These include investigator bias, which
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arises when a researcher interprets findings in the
context of preconceived viewpoints or adopts a
study design (e.g., exclusion criteria) that biases
the study results in the direction of the re-
searcher’s preconceived viewpoints. Investigator
bias is often unintentional. Similarly, obsolescence
bias may occur because medical technology used
during the periods covered by a retrospective data-
base is obsolete by the time the study is conducted.
Finally, bias is not the only statistical problem
that may undermine the validity of inferences
drawn from retrospective studies. Other problems
include the correlation of error terms among re-
spondents (autocorrelation), nonconstant variance
of error terms among respondents (heteroscedas-
ticity), and high correlation among explanatory
variables (multicollinearity).
 
What Alternative Methods for Assessing Selection 
Bias Are Available?
 
Perhaps the most fundamental area in which bias
occurs in a retrospective database analysis is dur-
ing selection of study subjects. Whereas RCTs re-
duce sample selection bias through randomization
by evenly distributing subjects among treatment
arms, retrospective database analyses are nonran-
domized. Nonrandomized studies that attempt to
evaluate treatment outcomes have been widely
criticized [5,6] because unobserved variables might
correlate with both treatment selection and out-
comes. Such a correlation can result in erroneous
inferences about the magnitude and statistical sig-
nificance of treatment effects.
Alternative methods for assessing selection bias
include using propensity scores, instrumental vari-
ables (IVs), and sample selection models; however,
these methods may fail to fully control for selec-
tion bias.
Propensity score analysis has received growing
attention as a methodology for reducing the bias
due to inherent differences between treatment
groups that go unobserved [7–9]. Although the
propensity score approach is nonparametric, An-
grist [10] has recently shown that propensity score
analysis may be more closely related to sample se-
lection models than previously believed.
The use of IVs in recent papers by McClellan
[11,12] has been proposed to control for the con-
founding effects of unobserved variables. Instru-
mental variables are widely used by researchers to
correct for a variety of statistical problems, most
notably, simultaneous equation bias and errors in
measurement [13].
Sample selection models attempt to control the
bias introduced by unobserved variables in treat-
ment selection, which are also correlated with the
outcome variable of interest. Sample selection
models have seen wide use in the econometrics lit-
erature to study labor supply decisions and to
model the effectiveness of job training programs,
housing programs, welfare experiments, and many
others [14]. Very recently, these models have be-
gun to find application in the health economics lit-
erature [15,16]. Selection models are a special case
of IVs and may require parameter estimates.
 
How Can Transparency Be Ensured in Retrospective 
Database Analyses?
 
A great deal of consensus exists among the guide-
lines about transparency of assumptions and meth-
ods [17]. Full disclosure and detailed methodology
when reporting study results of health economic
evaluations is recommended by the Uniform Re-
quirements for Manuscripts Submitted to Biomed-
ical Journals [18], the Task Force on Principles for
Economic Analysis of Healthcare Technology [19],
and the Pharmaceutical Research and Manufac-
turers of America’s Methodological and Conduct
Principles for Pharmacoeconomic Research [20].
One final point is that data privacy has become
an increased focus of attention. The International
Society of Pharmacoeconomics and Outcomes Re-
search (ISPOR) has recently adopted the data pri-
vacy recommendations developed by the Interna-
tional Society for Pharmacoepidemiology (ISPE
Data Privacy).
 
Recommendations and Next Steps
 
The credibility of retrospective database analyses
in health economic evaluations must be enhanced
by good research design, multiple and varied
checks on data quality, and attention to areas of
potential bias in a given study.
The following recommendations address the is-
sues identified:
• It is recommended that retrospective database
analysis studies begin with a clear question
and design, based on the International Society
for Pharmacoepidemiology guidelines for good
epidemiological practices [21].
• Privacy of individuals must be ensured at all
times in retrospective database analyses.
• Techniques that exist to address shortcomings
of retrospective data sets should be used.
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• Multivariate models should be subjected to ex-
tensive specification testing.
• Examining age- or gender-adjusted utilization
rates and annual per capita expense by payer,
health plan, geographic region, and country is
suggested.
• Administrative databases, frequently used for
retrospective pharmacoeconomic studies, need
to be augmented to include more clinical infor-
mation (e.g., the results of lab tests, not just an
indicator that a lab test was conducted).
• Bias is a threat to the validity of inferences
drawn from any retrospective and claims data-
base analysis. When bias exists, either real or
perceived, standard measures should be estab-
lished to deal with all areas of potential bias.
Methods of addressing specific types of bias in-
clude: (1) selection bias: modeling (e.g., Heck-
man approach, fixed-effect, and random-effect
models), propensity scores; (2) measurement
error and bias: modeling (e.g., bootstrap esti-
mation), data imputation; (3) misspecification
bias and other violations of model assump-
tions: conduct and report specification error
tests, select appropriate model and error distri-
bution, or adjust observations to remove the
specification error(s); (4) investigator bias: dis-
closure of conflict of interest, analysis assump-
tions, and study sponsor for investigator(s)
and key staff; (5) obsolescence bias: use expert
opinion to identify key innovative technologies
and model them, look at time trends in key uti-
lization parameters, and estimate models for
separate time periods; (6) vintage bias with re-
gard to human and physical capital: modeling,
link with other data sources such as an HCFA
area resource file.
 
Summary
 
Retrospective databases can be useful tools for
health economic evaluations. They offer large
populations using real-world information within
rapid and realistic treatment periods, and can an-
swer questions related to cost-effectiveness. Nev-
ertheless, pharmacoeconomic studies based upon
retrospective databases face a variety of threats to
the validity of the inferences drawn from them.
The credibility of retrospective database analyses
in health economic evaluations must be enhanced
by careful study design, elimination of bias, and
reporting the results of these studies in a clear, be-
lievable, and transparent fashion.
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